David R. Sage
Harvard University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by David R. Sage.
Nature Genetics | 2004
Young-Kwon Hong; Kimberly E. Foreman; Jay W. Shin; Satoshi Hirakawa; Christine L. Curry; David R. Sage; Towia A. Libermann; Bruce J. Dezube; Joyce D. Fingeroth; Michael Detmar
Kaposi sarcoma is considered a neoplasm of lymphatic endothelium infected with Kaposi sarcoma–associated herpesvirus. It is characterized by the expression of lymphatic lineage–specific genes by Kaposi sarcoma tumor cells. Here we show that infection of differentiated blood vascular endothelial cells with Kaposi sarcoma–associated herpesvirus leads to their lymphatic reprogramming; induction of ∼70% of the main lymphatic lineage–specific genes, including PROX1, a master regulator of lymphatic development; and downregulation of blood vascular genes.
Proceedings of the National Academy of Sciences of the United States of America | 2002
Andrea E. Prota; David R. Sage; Thilo Stehle; Joyce D. Fingeroth
Human complement receptor type 2 (CD21) is the cellular receptor for Epstein–Barr virus (EBV), a human tumor virus. The N-terminal two short consensus repeats (SCR1–SCR2) of the receptor interact with the EBV glycoprotein gp350/220 and also with the natural CD21 ligand C3d. Here we present the crystal structure of the CD21 SCR1–SCR2 fragment in the absence of ligand and demonstrate that it is able to bind EBV. Based on a functional analysis of wild-type and mutant CD21 and molecular modeling, we identify a likely region for EBV attachment and demonstrate that this region is not involved in the interaction with C3d. A comparison with the previously determined structure of CD21 SCR1–SCR2 in complex with C3d shows that, in both cases, CD21 assumes compact V-shaped conformations. However, our analysis reveals a surprising degree of flexibility at the SCR1–SCR2 interface, suggesting interactions between the two domains are not specific. We present evidence that the V-shaped conformation is induced by deglycosylation of the protein, and that physiologic glycosylation of CD21 would result in a more extended conformation, perhaps with additional epitopes for C3d binding.
Journal of Cell Science | 2004
Michael B. Gill; Jennifer Roecklein-Canfield; David R. Sage; Maria Zambela-Soediono; Nina Longtine; Marc E. Uknis; Joyce D. Fingeroth
CD21 is a multifunctional receptor for Epstein-Barr virus (EBV), for C3dg and for CD23. Upon engagement of immune complexes CD21 modulates immunoreceptor signaling, linking innate and adaptive immune responses. The mechanisms enabling CD21 to independently relay information between the exterior and interior of the cell, however, remain unresolved. We show that formin homologue overexpressed in spleen (FHOS/FHOD1) binds the cytoplasmic domain of human CD21 through its C terminus. When expressed in cells, EGFP-FHOS localizes to the cytoplasm and accumulates with actin in membrane protrusions. Plasma membrane aggregation, redistribution and co-localization of both proteins are stimulated when EBV (ligand) binds CD21. Though widely expressed, FHOS RNA is most abundant in the littoral cell, a major constituent of the red pulp of human spleen believed to function in antigen filtration. Formins are molecular scaffolds that nucleate actin by a pathway distinct from Arp2/3 complex, linking signal transduction to actin reorganization and gene transcription. Thus, ligand stimulation of FHOS-CD21 interaction may transmit signals through promotion of cytoskeletal rearrangement. Moreover, formin recruitment to sites of actin assembly initiated by immunoreceptors could be a general mechanism whereby co-receptors such as CD21 modulate intracellular signaling.
Journal of Virology | 2014
Mohamed S. Arredouani; Manoj Bhasin; David R. Sage; Laura Dunn; Michael B. Gill; Deep Agnani; Towia A. Libermann; Joyce D. Fingeroth
ABSTRACT Epstein-Barr virus (EBV) attachment to human CD21 on the B-cell surface initiates infection. Whether CD21 is a simple tether or conveys vital information to the cell interior for production of host factors that promote infection of primary B cells is controversial, as the cytoplasmic fragment of CD21 is short, though highly conserved. The ubiquity of CD21 on normal B cells, the diversity of this population, and the well-known resistance of primary B cells to gene transfer technologies have all impeded resolution of this question. To uncover the role(s) of the CD21 cytoplasmic domain during infection initiation, the full-length receptor (CD21 = CR), a mutant lacking the entire cytoplasmic tail (CT), and a control vector (NEO) were stably expressed in two pre-B-cell lines that lack endogenous receptor. Genome-wide transcriptional analysis demonstrated that stable CD21 surface expression alone (either CR or CT) produced multiple independent changes in gene expression, though both dramatically decreased class I melanoma-associated antigen (MAGE) family RNAs and upregulated genes associated with B-cell differentiation (e.g., C2TA, HLA-II, IL21R, MIC2, CD48, and PTPRCAP/CD45-associated protein). Temporal analysis spanning 72 h revealed that not only CR- but also CT-expressing lines initiated latency. In spite of this, the number and spectrum of transcripts altered in CR- compared with CT-bearing lines at 1 h after infection further diverged. Differential modulation of immediate early cellular transcripts (e.g., c-Jun and multiple histones), both novel and previously linked to CD21-initiated signaling, as well as distinct results from pathway analyses support a separate role for the cytoplasmic domain in initiation of intracellular signals. IMPORTANCE Membrane proteins that mediate virus attachment tether virus particles to the cell surface, initiating infection. In addition, upon virus interaction such proteins may transmit signals to the interior of the cell that support subsequent steps in the infection process. Here we show that expression of the Epstein-Barr virus B-cell attachment receptor, CD21, in B cells that lack this receptor results in significant changes in gene expression, both before and rapidly following EBV-CD21 interaction. These changes translate into major signaling pathway alterations that are predicted to support stable infection.
Journal of Virology | 1999
William L. Marshall; Ching Yim; Erik Gustafson; Thomas Graf; David R. Sage; Katherine Hanify; Louisa Williams; Joyce D. Fingeroth; Robert W. Finberg
Antimicrobial Agents and Chemotherapy | 1998
Erik Gustafson; Antoinette C. Chillemi; David R. Sage; Joyce D. Fingeroth
Journal of Virology | 1999
Joyce D. Fingeroth; Margaret E. Diamond; David R. Sage; Jody Hayman; John L. Yates
Blood | 2002
Bruce J. Dezube; Maria Zambela; David R. Sage; Jian-Feng Wang; Joyce D. Fingeroth
Blood | 1995
Ingrid Kuhn-Hallek; David R. Sage; Lincoln Stein; Holly Groelle; Joyce D. Fingeroth
Plasmid | 1998
David R. Sage; Antoinette C. Chillemi; Joyce D. Fingeroth